INmune Bio, Inc. (INMB) |
|
8.75 0.11 (1.27%)
|
02-03 15:31 |
|
Open: |
8.31 |
Pre. Close: |
8.64 |
|
High:
|
8.75 |
Low:
|
8.26 |
|
Volume:
|
32,186 |
Market Cap:
|
157(M) |
|
|
|
Technical analysis |
as of: 2023-02-03 3:18:15 PM |
|
Overall:
|
  |
| Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected. |
| Target: |
Six months: 10.96 One year: 12.81 |
| Support: |
Support1: 7.35  Support2: 6.09 |
| Resistance: |
Resistance1: 9.39 Resistance2: 10.96 |
| Pivot: |
8.23 |
| Moving Average: |
MA(5): 8.52 MA(20): 7.98
MA(100): 7.29 MA(250): 7.93 |
| MACD: |
MACD(12,26): 0.3 Signal(9): 0.2 |
| Stochastic oscillator: |
%K(14,3): 66.2 %D(3): 65.8 |
| RSI: |
RSI(14): 60.2 |
| 52-week: |
High: 11.77 Low: 4.62 |
| Average Vol(K): |
3-Month: 54 (K) 10-Days: 67 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ INMB ] has closed below upper band by 34.5%. Bollinger Bands are 5.6% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
8.99 - 9.04 |
9.04 - 9.08 |
|
Low:
|
8.34 - 8.39 |
8.39 - 8.44 |
|
Close:
|
8.51 - 8.6 |
8.6 - 8.68 |
|
Company Description |
|
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with high-risk myelodysplastic syndrome; INB03, an immunotherapy that treats patients with hematologic malignancies and solid tumors; and XPro1595 for the treatment of Alzheimer's disease. The company has license agreements with Xencor, Inc.; Immune Ventures, LLC; University of Pittsburg; and University College London. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. |
Headline News |
Wed, 25 Jan 2023
INmune Bio, Inc. Announces Pre-Clinical Data That Support a ... - GlobeNewswire
Tue, 24 Jan 2023
TB vaccination could be overall cost-effective in 73 of 105 LMICs (70 ... - EurekAlert
Mon, 16 Jan 2023
Here's Why INmune Bio (NASDAQ:INMB) Can Manage Its Debt Despite Losing Money - Simply Wall St
Thu, 05 Jan 2023
INmune Bio: INKmune For Solid Tumors And Other Potential ... - Seeking Alpha
Thu, 22 Dec 2022
INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer’s Disease - Yahoo Finance
Tue, 29 Nov 2022
INmune Bio, Inc. Focused on Novel Clinical Trial Designs to Advance Next Generation of Alzheimer’s Disease Treatments - Yahoo Finance
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
0 (M) |
| Shares Float |
18 (M) |
|
% Held by Insiders
|
1.166e+007 (%) |
|
% Held by Institutions
|
35 (%) |
|
Shares Short
|
914 (K) |
|
Shares Short P.Month
|
0 (K) |
Stock Financials |
|
EPS
|
0 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0 |
|
Profit Margin (%)
|
0 |
|
Operating Margin (%)
|
-6 |
|
Return on Assets (ttm)
|
647.7 |
|
Return on Equity (ttm)
|
-19.1 |
|
Qtrly Rev. Growth
|
440000 |
|
Gross Profit (p.s.)
|
306.12 |
|
Sales Per Share
|
-20.91 |
|
EBITDA (p.s.)
|
92346.9 |
|
Qtrly Earnings Growth
|
-2 |
|
Operating Cash Flow
|
0 (M) |
|
Levered Free Cash Flow
|
-27 (M) |
Stock Valuations |
|
PE Ratio
|
0 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
0 |
|
Price to Sales
|
-0.41 |
|
Price to Cash Flow
|
4.7 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
987010 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
